The global exosomes market size was estimated at USD 179 million in 2024 and is projected to be worth around USD 2,249.11 million by 2034, growing at a CAGR of 28.8% from 2025 to 2034.
Highlights of the Exosomes Market
- North America led the global market.
- Europe is projected to expand rapidly in the market in the coming years.
- By product and service, the kits and reagents product segment accounted for a considerable share of the market in 2024.
- By product and service, the services segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
- By workflow, the downstream analysis segment registered its dominance over the global market in 2024.
- By workflow, the isolation methods segment will gain a significant share of the market over the studied period of 2025 to 2034.
- By application, the cancer segment held a dominant presence in the market in 2024.
- By application, the infectious diseases segment is set to experience the fastest rate of market growth from 2025 to 2034.
- By end-use, the pharmaceutical & biotechnology companies segment dominated the global market in 2024.
- By end-use, the academic & research institutes segment is predicted to witness significant growth in the market over the forecast period.
Industry Valuation and Growth Rate Projection
| Industry Worth |
Details |
| Market Size in 2025 |
USD 230.55 Million |
| Market Size by 2034 |
USD 2249.11 Million |
| Market Growth Rate from 2025 to 2034 |
CAGR of 28.8% |
The exosomes market talks about exosomes, also called extracellular vesicles (EVs), which are bounded in the outer membrane and play a crucial role in cell-to-cell communication. These vesicles are emitted by different cell types that streamline intercellular communication through the transportation of proteins and nucleic acids to other cells. The important applications of exosomes include biomarkers, exosome therapy, drug delivery systems, and cancer vaccines.
Research and development in the field of exosomes has been receiving larger investments, particularly for finding new cancer biomarkers. The reason behind this is the increasing prevalence of cancer cases globally. As per the International Agency for Research on Cancer, a predictable number of new cancer diagnoses is 20 million, which was seen across the world in 2024.
Exosomes Market: Stats and Figures
- As per the data source GlobalData, the largest fields where exosomes are being delved into for clinical therapies involve oncology (54%), central nervous system (13%), infectious disease (13%), and immunology (8%).
- Exosomes are considered to be a substitute for stem cell-based therapy. Of the 40 clinical trials, 95% of these used MSC and the rest as the cellular source for exosomes.
How AI Has Benefitted the Market
The advent of AI has brought revolution to the exosome market. Using tools like the Predictive Clinical Exosome Tool (PERCEPTION) to merge exosomal RNA data to estimate immunotherapy responses, which is assisting the development of personalized treatment. The doctors are supported by AI in making real-time and informed decisions.
- Complex data analysis: The complicated molecular data rooted in Extracellular Vesicles (EVs) can be analyzed by AI technologies.
- Exosome workflows: AI creates a road map for examining the exosome so that the continuity of shifts from sample processing to clinical perceptions can be achieved.
- Generative Artificial Intelligence: Generative Artificial Intelligence (GenAI) can be utilized for tumor-targeting exosomal treatments and simplifying the intensification of exosome-driven cancer therapies.
- Accuracy: ML algorithms aid in analyzing exosomal protein profiles with precision in differentiating cancer-specific exosomes from non-cancerous ones.
Industry Leader Announcements
- Leigh Turner, a bioethicist and public health researcher at the University of California, Irvine.
“Exosomes have emerged as a sort of panacea for almost everything.”
- Dr. Tunc Tiryaki, Consultant Plastic Surgeon
“Exosomes are extracellular vesicles which are tiny bubbles released from stem cells. They act as building blocks, repair mechanisms and messengers, carrying genetic information and proteins to cells to perform different functions”
Geographical Insights
The exosomes market is subject to momentous growth as North America maintains its dominant position as a region in the market. As for Europe, the region is going to grow swiftly in the coming years. In the APAC region, countries like China, Japan, and India are steering the market growth.
North America
North America dominated the global exosomes market in 2024. There are some key factors responsible for this growth, like increasing amount of government funding for identification of new biomarkers and rise in the prolonged medical conditions such as cancer.
- As per the American Cancer Society (ACS), in the U.S., aside from non-melanoma skin cancers, more than 2 million new cancer cases are anticipated to be detected in 2025, and above 618,000 people may perhaps die due to cancer. Women and younger adults, specifically, will be more prone to the same.
Europe
Europe is anticipated to grow at the fastest rate in the forecast period, considering the market. This progress can be attributed to amplifying public-private collaborations amidst the region.
- In 2025, the new EVEREST project has brought together 21 top institutes and 11 countries to bring revolution to the study of extracellular vesicles (EVs). The funds have been received from the Marie Skłodowska-Curie Actions (MSCA) program beneath Horizon Europe, and the budget of the same is going to be €1,311,000 for 4 years, beginning in January 2025.
China and APAC
The Asia Pacific (APAC) region is going to witness tremendous growth in the exosomes market in the coming years. Countries like China and Japan are increasingly investing in the healthcare sector, particularly in the research and development of exosome-based analyses. The business collaborations, along with government support, are magnifying the market's capability.
- The Chinese government has come up with the Healthy China 2030 initiative, through which it has assigned ¥10 billion for precision medicine. This step is furthering the exosome research sector subtly by allowing extensive funding for linked endeavors.
Recent Developments:
- The Fudan University gave rise to a state-of-the-art AI tool termed ChatExosome, which can enhance the availability of diagnosing liver cancer, particularly hepatocellular carcinoma (HCC), by leveraging large language models (LLMs). · Capricor Therapeutics is a leading biotechnology company that announced the formulation of groundbreaking cell and exosome-based therapeutics for treating infrequent diseases.
Competitive Landscape
The exosomes market is progressively more competitive, with major companies like Thermo Fisher Scientific, Malvern Panalytical Ltd., Norgen Biotek Corp., Cell Guidance Systems Ltd., QIAGEN, and Bio-Techne taking the lead while holding the largest market share.
The market is dominated by several pharmaceutical firms celebrated for their noteworthy contributions to exosome-related treatment and diagnoses. Based on current data, the eminent three companies are:
- Company Name: Thermo Fisher Scientific
- Year of Incorporation: 2006
- Headquarters: Waltham, United States
The total revenue for the year 2024 was $42,879,000 for Thermo Fisher Scientific.
- Company Name: QIAGEN
- Year of Incorporation: 1984
- Headquarters: Venlo, Netherlands
The gross profit for QIAGEN tallied to $967,350.
- Company Name: Bio-Techne
- Year of Incorporation: 1981
- Headquarters: Minneapolis, United States
The total revenue of the company Bio-Techne elevated from 931,032 in 2021 to 1,159,060 in 2024.
